BiotechTube
Mosaic ImmunoEngineering

Mosaic ImmunoEngineering

San Diego, United States· Est.
mosaicie.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $31.5M

Overview

Mosaic ImmunoEngineering is a private, pre-revenue biotech firm leveraging synthetic biology to engineer immunotherapies for oncology and autoimmune conditions. The company recently expanded its pipeline through the acquisition of clinical-stage necroptosis cancer therapy assets from Oncotelic Therapeutics in April 2024. With an experienced leadership team featuring veterans from the biopharma industry, Mosaic is building a platform aimed at creating next-generation treatments. Its strategic focus combines internal platform development with asset acquisitions to accelerate progress.

OncologyAutoimmune Diseases

Technology Platform

Synthetic biology approaches to design novel immunotherapies, potentially combined with nanotechnology for targeted delivery or specific immune modulation.

Funding History

2
Total raised:$31.5M
Series A$26M
Seed$5.5M

Opportunities

The large and growing immunotherapy markets in oncology and autoimmunity present a significant opportunity.
The recent acquisition of clinical-stage necroptosis assets provides a near-term catalyst and a potential first-in-class or best-in-class pathway.
A successful synthetic biology platform could generate a sustainable pipeline of novel immunomodulators for multiple indications.

Risk Factors

High technical risk associated with developing novel, complex biological therapies.
Financial risk as a pre-revenue company dependent on external capital in a volatile funding environment.
Intense competition from large pharma and well-funded biotechs in the immunotherapy space.

Competitive Landscape

Mosaic competes in the highly crowded and competitive field of immunotherapy, dominated by large pharmaceutical companies with approved checkpoint inhibitors and cell therapies. It must differentiate through its synthetic biology platform's novelty and the specific mechanism of its acquired necroptosis assets. Success will depend on demonstrating superior efficacy, safety, or applicability to underserved patient populations.

More companies in Biologics / Biosimilars →More companies in United States →